A randomised phase II trial comparing gemcitabine vs TS-1 in patients with resected pancreatic cancer

A randomised phase II trial comparing gemcitabine vs TS-1 in patients with resected pancreatic cancer - Adjuvant Therapy for resected Pancreatic Cancer:TS-1 vs Gemcitabine

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003544

Enrollment

Registered

2010-04-27

Start date

2007-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Curative resection for pancreatic cancer

Interventions

gemcitabine TS-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: age (65 yrs</= or 64 yrs >) stage: I, II or III, IV tumor location (head or body-tail)

Exclusion criteria

Exclusion criteria: In patietns with preoperative chemo, chemo radiation. no good oral intake less than 20 yrs old PS 2 < (ECOG) poor fanction for bone marrow, liver, kidney and lung etc.

Design outcomes

Primary

Measure	Time frame
disease free survival	—

Secondary

Measure	Time frame
over all survival side effect QOL	—

Countries

Japan

Contacts

Public ContactTokihiko Sawada

Dokkyo Medical University Second Department of Surgery

tsawada@dokkyomed.ac.jp0282-87-2158

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026